File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Factors associated with the development of hepatocellular carcinoma after HBeAg seroclearance

TitleFactors associated with the development of hepatocellular carcinoma after HBeAg seroclearance
Authors
KeywordsMedical sciences
Gastroenterology
Issue Date2015
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
The 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD Liver Meeting 2015), San Francisco, CA., 13-17 November 2015. In Hepatology, 2015, v. 62 suppl. S1, p. 963A, abstract no. 1545 How to Cite?
AbstractBACKGROUND: The role of core promoter mutation, precore mutation, and genotype in the development of hepatocellular carcinoma (HCC) in patients after HBeAg seroclearance is unclear. METHODS: The CHB E-Seroclearance Study (C.H.E.S.S.) cohort follows up a large population of patients with documented HBeAg seroclearance. Surveillance for HCC was performed at regular intervals with alpha-fetoprotein and ultrasonography. This substudy includes patients who had precore and core promoter mutation and genotype determined at 3 to 24 months after the time of HBeAg seroclearance. RESULTS: A total of 293 CHB subjects were included with a median follow up of 124 months (range, 15 to 254) after HBeAg seroclearance, totaling 3,200 patient-years. The median age of HBeAg seroclearance was 34 years, of which 164 (56%) were male. The presence of core promoter and precore mutation was observed in 181 (61.8%) and 249 (85.0%) patients respectively. The majority of patients were of genotype C (88.1%). The cumulative rates of HCC at 5, 10 and 20 years after HBeAg seroclearance were 3.5%, 6.9%, and 8.8% respectively. There were a total of 19 cases of HCC, with a median time to HCC development (from the time of HBeAg seroclearance) of 57 months (range, 17 to 192). The median age of HCC development was 50 years (range, 33 to 72). Males had a significantly higher rate of HCC compared to females (12.5% vs 3.8% at 20 years respectively, p=0.037). The median age of HBeAg seroclearance was significantly higher for those who subsequently developed HCC compared to those without HCC (43 vs 34 years respectively, p<0.001). The presence of core promoter mutation was associated with significantly higher rate of HCC (18.5% vs 2.3% respectively, p<0.001). There was no significant difference in HCC development with respect to the presence of precore mutation or with viral genotype (p=0.55 and p=0.69 respectively). There was no significant difference between those with spontaneous versus those who received antiviral therapy at the time of HBeAg seroclearance (p=0.17). A higher median HBV DNA was observed for those with HCC compared to those without (6.79 vs 4.76 log copies/mL respectively, P=0.041). CONCLUSION: In patients undergoing HBeAg seroclearance, male sex, older age at the time of HBeAg seroclearance, higher HBV DNA and the presence of core promoter mutation after HBeAg seroclearance was associated with higher rates of HCC development.
DescriptionPoster Session 3 - Hepatitis B: Epidemiology and Natural History: no. 1545
This FREE journal suppl. entitled: Special Issue: The 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015
Persistent Identifierhttp://hdl.handle.net/10722/226490
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752

 

DC FieldValueLanguage
dc.contributor.authorFung, J-
dc.contributor.authorLai, CL-
dc.contributor.authorWong, D-
dc.contributor.authorSeto, WK-
dc.contributor.authorYuen, MF-
dc.date.accessioned2016-06-17T07:44:29Z-
dc.date.available2016-06-17T07:44:29Z-
dc.date.issued2015-
dc.identifier.citationThe 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD Liver Meeting 2015), San Francisco, CA., 13-17 November 2015. In Hepatology, 2015, v. 62 suppl. S1, p. 963A, abstract no. 1545-
dc.identifier.issn0270-9139-
dc.identifier.urihttp://hdl.handle.net/10722/226490-
dc.descriptionPoster Session 3 - Hepatitis B: Epidemiology and Natural History: no. 1545-
dc.descriptionThis FREE journal suppl. entitled: Special Issue: The 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015-
dc.description.abstractBACKGROUND: The role of core promoter mutation, precore mutation, and genotype in the development of hepatocellular carcinoma (HCC) in patients after HBeAg seroclearance is unclear. METHODS: The CHB E-Seroclearance Study (C.H.E.S.S.) cohort follows up a large population of patients with documented HBeAg seroclearance. Surveillance for HCC was performed at regular intervals with alpha-fetoprotein and ultrasonography. This substudy includes patients who had precore and core promoter mutation and genotype determined at 3 to 24 months after the time of HBeAg seroclearance. RESULTS: A total of 293 CHB subjects were included with a median follow up of 124 months (range, 15 to 254) after HBeAg seroclearance, totaling 3,200 patient-years. The median age of HBeAg seroclearance was 34 years, of which 164 (56%) were male. The presence of core promoter and precore mutation was observed in 181 (61.8%) and 249 (85.0%) patients respectively. The majority of patients were of genotype C (88.1%). The cumulative rates of HCC at 5, 10 and 20 years after HBeAg seroclearance were 3.5%, 6.9%, and 8.8% respectively. There were a total of 19 cases of HCC, with a median time to HCC development (from the time of HBeAg seroclearance) of 57 months (range, 17 to 192). The median age of HCC development was 50 years (range, 33 to 72). Males had a significantly higher rate of HCC compared to females (12.5% vs 3.8% at 20 years respectively, p=0.037). The median age of HBeAg seroclearance was significantly higher for those who subsequently developed HCC compared to those without HCC (43 vs 34 years respectively, p<0.001). The presence of core promoter mutation was associated with significantly higher rate of HCC (18.5% vs 2.3% respectively, p<0.001). There was no significant difference in HCC development with respect to the presence of precore mutation or with viral genotype (p=0.55 and p=0.69 respectively). There was no significant difference between those with spontaneous versus those who received antiviral therapy at the time of HBeAg seroclearance (p=0.17). A higher median HBV DNA was observed for those with HCC compared to those without (6.79 vs 4.76 log copies/mL respectively, P=0.041). CONCLUSION: In patients undergoing HBeAg seroclearance, male sex, older age at the time of HBeAg seroclearance, higher HBV DNA and the presence of core promoter mutation after HBeAg seroclearance was associated with higher rates of HCC development.-
dc.languageeng-
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/-
dc.relation.ispartofHepatology-
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.-
dc.subjectMedical sciences-
dc.subjectGastroenterology-
dc.titleFactors associated with the development of hepatocellular carcinoma after HBeAg seroclearance-
dc.typeConference_Paper-
dc.identifier.emailFung, J: jfung@hkucc.hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hkucc.hku.hk-
dc.identifier.emailWong, D: danywong@hku.hk-
dc.identifier.emailSeto, WK: wkseto@hku.hk-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.authorityFung, J=rp00518-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.authorityWong, D=rp00492-
dc.identifier.authoritySeto, WK=rp01659-
dc.identifier.authorityYuen, MF=rp00479-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/hep.28233-
dc.identifier.hkuros258655-
dc.identifier.volume62-
dc.identifier.issuesuppl. S1-
dc.identifier.spage963A, abstract no. 1545-
dc.identifier.epage963A, abstract no. 1545-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats